Business
ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV™ at CIS 2022
RAMSEY, N.J. and BOCA RATON, Fla., April 01, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial
About this update from Adma Biologics Inc
[{"type":"text","content":"RAMSEY, N.J. and BOCA RATON, Fla., April 01, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced a poster presentation and exclusive Key Opinion Leader symposium by nationally recognized clinical experts on the management of respiratory viral infections (RVIs) and real-world experience with ADMA’s ASCENIV, a U.S. Food and Drug Administration (FDA)-approved intravenous immunoglobulin (IVIG) product with a unique composition. Poster Presentation Title: ASCENIV™ Reduces Viral Infections and Associated Comorbidities in a Primary Immunodeficiency PatientSession Date: Friday, April 1, 2022Session Time: 1:00 PM – 2:00 PM ET Session Location: Exhibit Hall, Symphony Ballroom, Sheraton Charlotte Hotel, 55 South McDowell Street South Tower, Charlotte, NCPoster Presentation and Abstract Number: #47 Kevin Rosenbach, MD, Medical Director of Naples Allergy & Immunology Center, will share a live poster presentation of real-world outcomes of ASCENIV, involving a challenging case of a patient diagnosed with late-onset combined immunodeficiency (LOCID) with a history of chronic and recurrent respiratory infections. Educational Event Presentation Title: Challenges Associated with Respiratory Viral Infections (RVIs) in patients with Primary Immunodeficiency: An Expert Discussion & Real-World Experience Session Date: Saturday, April 2, 2022Session Time: 12:45 PM – 1:45 PM ET Session Location: Sheraton Charlotte Hotel, 55 South McDowell Street South Tower, Charlotte, NC. Room Mecklenberg 1 Jolan Walter, MD, PhD, Division Chief of the University of South Florida (USF) and Johns Hopkins All Children’s Pediatric Allergy & Immunology Programs, will discuss risk factors, unmet clinical needs, and key considerations in the management of RVIs in patients with primary immunodeficiency.Dareen Siri, MD, FAAAAI FACAAI FISAAI, Medical Director at Midwest Allergy Sinus Asthma, will present on the management of immunoglobulin therapy, introduce the clinical profile of ASCENIV™, and discuss its clinical use in four challenging patient cases with a history of respiratory infections and multiple comorbid, chronic conditions. About ASCENIV™ ASCENIV (immune globulin intravenous, hu...